h5n1 antigen
Vaccineexperimental
Clinical trial activity
3 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 18, 2020 (NCT04669691)
Timeline
Indications
Studied for
Mechanism of action
- Influenza A virusImmunity, active
Influenza A virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06560151 | Phase 2 | Aug 21, 2024 | Department of Health and Human Services, ICON, Rho, Inc. |
| NCT05397119 | Phase 1 | Jul 7, 2022 | BlueWillow Biologics, National Institute of Allergy and Infectious Diseases (NIAID), University of Maryland |
| NCT04669691 | Phase 2 | Dec 18, 2020 | CSL Behring |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BlueWillow Biologics | For profit | 1 | 1 | 1 | 2022 |
| CSL Behring | For profit | 1 | 1 | 1 | 2020 |
| Department of Health and Human Services | Government | 1 | 1 | 1 | 2024 |
| ICON | For profit | 1 | 0 | 1 | 2024 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2022 |
| Rho, Inc. | For profit | 1 | 0 | 1 | 2024 |
| University of Maryland | Academic/Hospital | 1 | 0 | 1 | 2022 |
7 organizations
Page 1 / 1